Dianthus Therapeutics, Inc. /DE/ (DNTH) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
DNTH currently has 54.7M outstanding shares. with significant dilution risk as 148M authorized shares could dilute existing holders by 271.0%. The company has significantly diluted shareholders by 74.18% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 54.7M shares outstanding |
55M | 150M |
| Jan 28, 2026 |
S-3 filing: The company is offering up to $600,000,000 of common stock, preferred stock, debt securities, warrants and/or units. |
43M | 160M |
| Nov 05, 2025 |
10-Q filing | 42.9M shares outstanding |
43M | 150M |
| Aug 07, 2025 |
10-Q filing | 32.2M shares outstanding |
32M | 160M |
| May 12, 2025 |
10-Q filing | 32.2M shares outstanding |
32M | 160M |
| Mar 11, 2025 |
10-K filing | 33.3M shares outstanding |
33M | 160M |
| Nov 07, 2024 |
10-Q filing | 29.6M shares outstanding |
30M | 160M |
| Oct 21, 2024 |
RW filing: Request to withdraw registration statement on Form S-1 for resale of common stock by selling stockholders, as the shares are being registered in a new registration statement on Form S-3. |
29M | 160M |
| Oct 01, 2024 |
S-3 filing: The filing is an S-3 form registering common stock, preferred stock, and debt securities for potential issuance up to $500,000,000, with a focus on an at-the-market offering of common stock through TD Cowen for up to $200,000,000 to fund preclinical and clinical development activities, working capital, and general corporate purposes. |
29M | 180M |
| Oct 01, 2024 |
S-3 filing: This is an S-3 filing for a resale of common stock by selling stockholders. |
29M | 180M |
| Aug 08, 2024 |
10-Q filing | 29.4M shares outstanding |
29M | 81M |
| May 09, 2024 |
10-Q filing | 29.3M shares outstanding |
29M | 81M |
| Mar 21, 2024 |
S-1/A filing: This S-1/A filing from Dianthus Biosciences details the offering of up to 16,450,336 shares of common stock and 4,876,652 shares of common stock issuable upon the exercise of Pre-Funded Warrants by selling stockholders. |
29M | 81M |
| Mar 21, 2024 |
10-K filing | 29.3M shares outstanding |
29M | 81M |
| Feb 07, 2024 |
S-1/A filing: This S-1/A filing registers 21,326,988 shares of common stock for resale by selling stockholders. |
29M | 81M |
| Dec 21, 2023 |
S-1/A filing: This S-1/A filing from 2023-12-21 details an offering of up to 5,253,681 shares of common stock and 210,320 shares of common stock issuable upon the exercise of Pre-Funded Warrants by selling stockholders. The company will not receive any proceeds from the sale, except for a nominal amount upon exercise of the Pre-Funded Warrants. |
15M | 80M |
| Nov 09, 2023 |
10-Q filing | 14.8M shares outstanding |
15M | 80M |
| Oct 04, 2023 |
S-3 filing: This is an S-3 filing for the resale of 5,464,001 shares of common stock by selling stockholders. |
61M | 34M |
| Aug 03, 2023 |
10-Q filing | 60.7M shares outstanding |
61M | 28M |
| May 15, 2023 |
10-Q filing | 60.6M shares outstanding |
61M | 28M |
| Mar 23, 2023 |
10-K filing | 59.4M shares outstanding |
59M | 30M |
| Nov 03, 2022 |
10-Q filing | 59.3M shares outstanding |
59M | 30M |
| Aug 04, 2022 |
10-Q filing | 58.8M shares outstanding |
59M | 30M |
| Aug 04, 2022 |
S-3 filing: The company may issue up to $250,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. They are also offering common stock through an at the market offering. |
59M | 30M |
| May 16, 2022 |
10-Q filing | 58.8M shares outstanding |
59M | 0 |
| Mar 08, 2022 |
10-K filing | 54.9M shares outstanding |
55M | 3.3M |
| Nov 04, 2021 |
10-Q filing | 58.8M shares outstanding |
59M | 0 |
| Aug 05, 2021 |
10-Q filing | 58.6M shares outstanding |
59M | 0 |
| Jun 25, 2021 |
S-3 filing: The filing relates to the offer and resale of up to 9,599,998 shares of common stock by selling stockholders, who received the shares in a private placement. The company will not receive any proceeds from the sale. |
49M | 9.6M |
| May 06, 2021 |
10-Q filing | 48.6M shares outstanding |
49M | 0 |
| Mar 03, 2021 |
10-K filing | 48.6M shares outstanding |
49M | 0 |
| Nov 05, 2020 |
10-Q filing | 48.3M shares outstanding |
48M | 0 |
| Aug 06, 2020 |
10-Q filing | 48.3M shares outstanding |
48M | 0 |
| May 07, 2020 |
10-Q filing | 39.5M shares outstanding |
39M | 0 |
| Mar 03, 2020 |
10-K filing | 39.3M shares outstanding |
39M | 0 |